1. BioGuard Science Overview
  2. Research Reference on BLIS K12
  3. How BioGuard Works

BioGuard Science

Research References on BioGuard Ingredient BLIS K12

Below is a list of the top research references for BioGuard ingredient BLIS K12 in such areas as immunity and safety.

Tagg et al. (2008) - New Zealand

Streptococci as effector organisms for probiotic and replacement therapy. Therapeutic Microbiology: Probiotics and Other Therapies. Edited by Versalovic J & Wilson M (American Society for Microbiology Press)

Horzet al. (2007) - Germany

Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. Oral Microbiol Immunol. 2007 Apr;22 (2):126-30.

Tagg et al. (2006) - New Zealand

Oral streptococcal BLIS: Heterogeneity of the effector molecules and potential role in the prevention of streptococcal infections, International Congress Series, 2006, Vol 128: 347-350

Tagg et al. (2004) - New Zealand

Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like (BLIS) produced by Streptococcus salivarius. Indian J Med Res. 2004 May;119 Suppl:13-6.

Tagg et al. (2003) - New Zealand

Bacterial replacement therapy: adapting 'germ warfare' to infection prevention. Trends in Biotechnology. 21(5):217-23.

Power et al. (2008) - New Zealand

Preliminary investigations of the colonization of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis. 2008 Jun 17.

Cosseauet et al. (2008) - Canada & UK

The commensal Streptococcus salivarius K12 down-regulates the innate immune responses of human epithelial cells and promotes host- microbe homeostasis. Infection and Immunity, Sept. 2008, p. 4163–4175

Tagg et al. (2008) - New Zealand

Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media? J Med Microbiol. 2003 Sep;52(Pt 9):829- 33.

James and Tagg (1991) - New Zealand

The prevention of dental caries by BLIS-mediated inhibition of mutans streptococci N Z Dent J. 1991 Jul; 87(389):80-3.

Burtonet al. (2006) - New Zealand

A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters, Journal of Applied Microbiology 754-64.

Burtonet al. (2005) - New Zealand

The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics, Oral Diseases (2005) 11 (Suppl. 1), 29–31

Wescombeet al. (2006) - New Zealand

Megaplasmids encode differing combinations of lantibiotics in Streptococcus salivarius, Antonie Van Leeuwenhoek. 2006 Oct;90 (3):269-80

Tagg et al. (2003) - New Zealand

Bacterial replacement therapy: adapting ‘germ warfare’ to infection prevention, Trends Biotechnol. 2003 May;21 (5):217-23.

Heng et al. (2006) - New Zealand

The Diversity of bacteriocins produced by Gram-positive bacteria. (Book Chapter) Evolution and Ecology of Bacteriocins. Springer New York, Editor: M Riley.

Hyink et al. (2007) - New Zealand

Salivaricin A2 and the novel antibiotic salivaricin B, are encoded by adjacent loci on a 190 kb transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol 73(4): 1107-13.

Wescombe et al. (2006) - New Zealand

Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Appl Environ Microbiol. 2006 Feb;72(2):1459-66.

Burtonet al. (2006) - New Zealand

Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Appl Environ Microbiol. 2006 Apr;72(4):3050-3. Immunity